Clinical trial
Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer
NCT00257348 · University of California, Irvine, Other · Completed
Key facts
| NCT number | NCT00257348 |
|---|---|
| Title | Capecitabine and Docetaxel in Advanced/Recurrent Cervical Cancer |
| Official title | A Phase II Trial of Capecitabine and Docetaxel in the Treatment of Advanced and Recurrent Cervical Cancer |
| Lead sponsor | University of California, Irvine, Other |
| Collaborators | Aventis Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cervical Cancer |
| Intervention type | Drug |
| Interventions | Capecitabine, Docetaxel |
| Enrollment | 5 |
| Start date | Mar 1, 2004 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Nov 22, 2005 |
| Last update posted | Feb 8, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: